Updated versions of best-selling drugs may partially mitigate the impact of the loss of the patent cliff. The patent cliff occurs after patent protection for originator drugs expires, allowing generic drugs to enter the market[1][2]. The renewal of these drugs represents one option to combat this phenomenon[4][10]. However, this approach has its limits and is not sufficient to fully address the problem. The key to successfully tackling the situation is the right strategy by the originator manufacturers. Patent protection usually lasts for 25 years and protects the exclusive right to manufacture and sell[2][3]. After it expires, generics produce the same active ingredient in the same form[1][6].